Genetic or pharmacological inhibition of FAK leads to reduced proliferation and increased cell death in KRAS mutant lung cancer cells, while sparing cells carrying wild-type KRAS (Konstantinidou et al, 2013) (Fig. 1A). Here, KRAS is linked to lung carcinoma.